52.61
-0.90 (-1.68%)
| Previous Close | 53.51 |
| Open | 51.80 |
| Volume | 1,802,301 |
| Avg. Volume (3M) | 2,048,036 |
| Market Cap | 5,013,745,152 |
| Price / Earnings (Forward) | 23.36 |
| Price / Sales | 121.80 |
| Price / Book | 2.42 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -17,158.84% |
| Diluted EPS (TTM) | -4.49 |
| Quarterly Revenue Growth (YOY) | 71.60% |
| Total Debt/Equity (MRQ) | 11.99% |
| Current Ratio (MRQ) | 15.64 |
| Operating Cash Flow (TTM) | -306.47 M |
| Levered Free Cash Flow (TTM) | -193.24 M |
| Return on Assets (TTM) | -12.88% |
| Return on Equity (TTM) | -19.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | CRISPR Therapeutics AG | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Value |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 76.46% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (Citizens, 52.06%) | Buy |
| 80.00 (Needham, 52.06%) | Buy | |
| Median | 78.50 (49.21%) | |
| Low | 74.00 (Chardan Capital, 40.66%) | Buy |
| Average | 77.75 (47.79%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 52.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citizens | 30 Jan 2026 | 80.00 (52.06%) | Buy | 49.96 |
| 23 Dec 2025 | 86.00 (63.47%) | Buy | 56.46 | |
| Needham | 23 Dec 2025 | 80.00 (52.06%) | Buy | 56.46 |
| Chardan Capital | 26 Nov 2025 | 74.00 (40.66%) | Buy | 53.30 |
| Citigroup | 12 Nov 2025 | 77.00 (46.36%) | Buy | 52.19 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine |
| 12 Jan 2026 | Announcement | CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones |
| 05 Jan 2026 | Announcement | CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 02 Jan 2026 | Announcement | Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize |
| 22 Dec 2025 | Announcement | CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies |
| 09 Dec 2025 | Announcement | Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |